IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+43.34%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$350M
AUM Growth
+$350M
(+8.8%)
Cap. Flow
+$11.3M
Cap. Flow
% of AUM
3.22%
Top 10 Holdings %
Top 10 Hldgs %
41.9%
Holding
166
New
42
Increased
21
Reduced
58
Closed
16
Top Buys
| 1 |
Scholar Rock
SRRK
|
$15.4M |
| 2 |
Forte Biosciences
FBRX
|
$13.8M |
| 3 |
TG Therapeutics
TGTX
|
$8.77M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$7.36M |
| 5 |
Vir Biotechnology
VIR
|
$6.59M |
Top Sells
| 1 |
Tarsus Pharmaceuticals
TARS
|
$23.4M |
| 2 |
Soleno Therapeutics
SLNO
|
$11.2M |
| 3 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$5.76M |
| 4 |
Arcus Biosciences
RCUS
|
$5.44M |
| 5 |
Capricor Therapeutics
CAPR
|
$4.56M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Terns Pharmaceuticals
TERN
$651M
| $1.71M | 0.23% |
308,491
-6
| -0% | -$33 |
|
|
ACHL
52
DELISTED
Achilles Therapeutics plc American Depositary Shares
ACHL
| $1.64M | 0.22% |
1,441,141
-2,040
| -0.1% | -$2.33K |
|
53
Immunic
IMUX
$79.4M
| $1.61M | 0.22% |
1,614,170
+1,120,674
| +227% | +$1.12M |
|
54
Alto Neuroscience
ANRO
$97.7M
| $1.48M | 0.2% |
+350,000
| New | +$1.48M |
|
55
iBio
IBIO
$16.9M
| $1.47M | 0.2% |
599,913
-87
| -0% | -$213 |
|
56
Cidara Therapeutics
CDTX
$1.61B
| $1.45M | 0.2% |
+53,940
| New | +$1.45M |
|
57
Tourmaline Bio
TRML
$645M
| $1.38M | 0.19% |
67,927
-40,556
| -37% | -$822K |
|
|
SWTX
58
DELISTED
SpringWorks Therapeutics
SWTX
| $1.36M | 0.18% |
+37,519
| New | +$1.36M |
|
59
Trevi Therapeutics
TRVI
$871M
| $1.34M | 0.18% |
+325,000
| New | +$1.34M |
|
60
Delcath Systems
DCTH
$381M
| $1.21M | 0.16% |
100,365
-5
| -0% | -$60 |
|
61
Jasper Therapeutics
JSPR
$44.2M
| $1.18M | 0.16% |
55,107
-68
| -0.1% | -$1.45K |
|
|
ALLK
62
DELISTED
Allakos
ALLK
| $1.18M | 0.16% |
971,950
-725
| -0.1% | -$877 |
|
63
Lexicon Pharmaceuticals
LXRX
$392M
| $1.14M | 0.16% |
+1,550,000
| New | +$1.14M |
|
64
Milestone Pharmaceuticals
MIST
$151M
| $1.1M | 0.15% |
466,030
+11
| +0% | +$26 |
|
|
THRD
65
DELISTED
Third Harmonic Bio
THRD
| $1.03M | 0.14% |
+100,000
| New | +$1.03M |
|
|
VERV
66
DELISTED
Verve Therapeutics
VERV
| $959K | 0.13% |
169,991
-9
| -0% | -$51 |
|
67
Pyxis Oncology
PYXS
$91.2M
| $957K | 0.13% |
613,253
-344,155
| -36% | -$537K |
|
68
Fulcrum Therapeutics
FULC
$353M
| $940K | 0.13% |
200,096
+125,096
| +167% | +$588K |
|
69
Cartesian Therapeutics
RNAC
$267M
| $934K | 0.13% |
52,166
-27
| -0.1% | -$484 |
|
70
Traws Pharma
TRAW
$11.4M
| $875K | 0.12% |
+98,493
| New | +$875K |
|
71
Aclaris Therapeutics
ACRS
$223M
| $868K | 0.12% |
+350,000
| New | +$868K |
|
|
VIGL
72
DELISTED
Vigil Neuroscience
VIGL
| $850K | 0.12% |
+500,000
| New | +$850K |
|
73
Tyra Biosciences
TYRA
$657M
| $834K | 0.11% |
+60,000
| New | +$834K |
|
74
Lyell Immunopharma
LYEL
$220M
| $817K | 0.11% |
63,802
+37,499
| +143% | +$480K |
|
|
CMPS
75
Compass Pathways
CMPS
$452M
| $767K | 0.1% |
202,894
-14
| -0% | -$53 |
|